The current study suggests that this failure to activate AMPK in response to contraction could be bypassed by pharmacological intervention, and contributes to the evidence base for a clinical trial of an AMPK activator in ME/CFS. This evidence concerns the gene PRKAA1 and myalgic encephalomeyelitis/chronic fatigue syndrome.